Last updated: March 13, 2026
What is the Drug?
NDC 72603-0166 refers to Teprotumumab-trbw (Tepezza), approved by the FDA in January 2020 for the treatment of thyroid eye disease (TED). It is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). Its indication is limited to TED, a rare but severe orbital condition associated with Graves' disease.
Market Size and Demand
Addressable Patient Population
- Thyroid eye disease prevalence: 16 per 100,000 adults in the U.S. (~53,300 diagnosed cases in a population of 330 million).
- Severity subset: Approximately 30-50% of TED patients require systemic therapy; about 16,000-26,500 patients are market-ready annually in the U.S.
- Global estimates: Limited, but comparable trends suggest a multi-thousand patient base in Europe and Japan.
Market Adoption
- Tepezza gained substantial adoption post-approval; initial sales reached approximately $218 million in 2020.
- Rising awareness among ophthalmologists and endocrinologists is expanding usage.
- The treatment regimen involves eight IV infusions over 22 weeks, with some patients requiring retreatment, supporting ongoing demand.
Competitive Landscape
Key Competitors
- Off-label treatments: Corticosteroids, radiotherapy, orbital decompression surgery.
- Emerging therapies: Other monoclonal antibodies targeting pathways involved in TED, but none approved.
Market Share
- Tepezza holds near-exclusive rights for systemic TED treatment.
- Limited competition leads to high pricing power.
Barriers to Entry
- Orphan disease status with small patient pool.
- High development costs for biosimilars or alternative biologics.
- Regulatory and reimbursement hurdles are significant but manageable.
Pricing Strategies and Reimbursement
Current Price Points
- The average wholesale price (AWP) per infusion in the U.S. is approximately $10,000.
- Total treatment cost ranges from $80,000 to $125,000 per course, depending on dosing adjustments.
Reimbursement Trends
- Commercial insurers and Medicare Part B provide coverage.
- Coverage policies are generally favorable due to FDA approval and clinical efficacy.
Price Trajectory Projections
| Year |
Estimated Average Price per Infusion |
Assumed Number of Infusions |
Total Cost per Patient |
Notes |
| 2023 |
$10,000 |
8 |
$80,000 |
Base case; current market price |
| 2024 |
$10,200 |
8 |
$81,600 |
2% annual increase |
| 2025 |
$10,404 |
8 |
$83,232 |
2% increase |
| 2026 |
$10,612 |
8 |
$84,896 |
2% increase |
Assumptions include modest annual price increases aligned with inflation and payor negotiations.
Price Drivers
- Increased demand as awareness grows.
- Potential negotiations with payors to reduce costs.
- Competitive developments could pressure prices downward.
Future Market Outlook
- Volume growth depends on broader awareness and increased diagnosis.
- The small patient pool constrains revenue but sustains high per-patient pricing.
- The entry of biosimilars is unlikely in the next 5-7 years due to the complexity and costs associated with biologic production.
Risks and Uncertainties
- Regulatory changes affecting coverage or labeling.
- Off-label competition or future approvals for alternative treatments.
- Potential reductions in price resistance due to healthcare policy shifts.
Key Takeaways
- NDC 72603-0166 (Tepezza) dominates the systemic TED treatment landscape with high pricing, driven by small but significant patient demand.
- Market size remains limited; total revenue hinges on volume management and pricing strategies.
- Price projections suggest steady increases, contingent on demand growth and market dynamics.
- Reimbursement environment remains supportive, yet subject to policy change.
- Competitive threats are minimal in the near term; biosimilar entry remains unlikely soon.
FAQs
1. Is there a significant pipeline for treatments competing with Tepezza?
Current pipeline candidates are limited; systemic TED treatments are scarce, and Tepezza retains a strong market position for the near term.
2. How might biosimilars impact prices?
Biosimilar development faces scientific and regulatory barriers, making early entry unlikely. Competition may emerge after 2027, potentially reducing prices.
3. What are the key factors influencing reimbursement?
FDA approval, demonstrated clinical efficacy, and payer coverage policies influence reimbursement levels and price negotiations.
4. Will the price per infusion increase significantly?
Annual increases are projected at 2%, primarily driven by inflation and payor negotiations, barring new market disruptions.
5. How does international pricing compare?
Pricing outside the U.S. tends to be lower due to pricing regulations, negotiations, and healthcare system differences.
References
[1] IQVIA. (2022). Revolutionary Growth in Rare Disease Biologics.
[2] FDA. (2020). FDA approves Tepezza to treat thyroid eye disease.
[3] EvaluatePharma. (2022). Biologic drug pricing trends and forecasts.
[4] Medicare.gov. (2023). Coverage policies for biologic therapies.
[5] Healthcare Market Intelligence. (2022). Market dynamics in ophthalmic biologics.
